Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-04

Clinical Trial Update: Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) [Phase 1]

View source ↗

Summary

KRYSTAL 2 is a Phase 1 trial evaluating adagrasib in combination with TNO155 in patients with advanced or metastatic cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Adagrasib (adagrasib)
  • TNO155 (TNO155)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Cancer, Metastatic Cancer | Phase 1 | Status: COMPLETED